Monitoring the Efficacy of a Probiotic Dietary Supplement SmartProbio C in Patients With Severe COVID-19 Infection

NACompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
COVID-19
Interventions
DIETARY_SUPPLEMENT

SmartProbio C

Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.

DIETARY_SUPPLEMENT

Placebo

Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.

Trial Locations (2)

61200

Medi Pharma Vision, Brno

62500

Brno University Hospital, Brno

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Veterinary Research Institute

UNKNOWN

collaborator

Brno University Hospital

OTHER

lead

Medi Pharma Vision

INDUSTRY

NCT05474144 - Monitoring the Efficacy of a Probiotic Dietary Supplement SmartProbio C in Patients With Severe COVID-19 Infection | Biotech Hunter | Biotech Hunter